BTIG analyst Mark Massaro announced an increased price target for IDEXX Laboratories (NASDAQ:IDXX), raising it from $500 to $530, while maintaining a Buy rating on the stock. The revision follows ...
HOPE has announced plans to assemble a best-in-class global network of interventional psychiatry clinics combining ketamine treatment with transcranial magnetic stimulation, and digital therapeutics ...
HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, ...
In a report released today, Clark Lampen from BTIG maintained a Buy rating on DraftKings (DKNG – Research Report), with a price target of ...
BTIG analyst David Larsen adjusted the firm's stance on IQVIA Holdings (NYSE:IQV), moving from a Buy rating to Neutral. The $36.5 billion market cap company, currently trading near its 52-week low at ...
BTIG downgraded MGM Resorts (MGM) to Neutral from Buy ahead of the Q4 earnings report. The firm is optimistic around iGaming market expansion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback